Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Replimune Group Inc (REPL)
NASDAQ:REPL
REPL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.92 - $17.00
Previous CloseN/A
Volume95.41K
Average Volume (3M)735.00K
Market Cap
$1.08B
Enterprise Value$505.19M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.51
Next Earnings
May 15, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.14
Shares Outstanding77,014,780
10 Day Avg. Volume535,717
30 Day Avg. Volume735,001
Standard Deviation0.24
R-Squared0.08
Alpha0.00497
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-190.28
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$22.83Price Target Upside59.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyRP1 + Opdivo achieved an objective response rate of 33.6%, which is significantly higher than what would be expected with an anti-PD1 agent alone in an anti-PD1-refractory melanoma population.
Financial PositionReplimune's cash position firmly sets up the company for a strong launch and further development of its portfolio.
Regulatory ProgressThe FDA granted breakthrough therapy designation for RP1 + nivolumab in anti-PD-1-failed melanoma.
Bears Say
Development RisksRP2 is being developed in uveal melanoma and hepatocellular carcinoma, with new trials enrolling patients and expanding its research scope.
Market CompetitionReplimune's RP1 + Opdivo combination therapy shows potential differentiation against other treatments like Amtagvi™ due to its efficacy and safety profile.
Regulatory UncertaintyThe FDA has accepted REPL's BLA for RP1 and granted priority review, with a PDUFA date set for July 22, 2025.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
REPL FAQ
What was Replimune Group Inc’s price range in the past 12 months?
Replimune Group Inc lowest stock price was $4.92 and its highest was $17.00 in the past 12 months.
What is Replimune Group Inc’s market cap?
Replimune Group Inc’s market cap is $1.08B.
When is Replimune Group Inc’s upcoming earnings report date?
Replimune Group Inc’s upcoming earnings report date is May 15, 2025 which is in 83 days.
How were Replimune Group Inc’s earnings last quarter?
Replimune Group Inc released its earnings results on Feb 06, 2025. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.706 by -$0.084.
Is Replimune Group Inc overvalued?
According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued.
Does Replimune Group Inc pay dividends?
Replimune Group Inc does not currently pay dividends.
What is Replimune Group Inc’s EPS estimate?
Replimune Group Inc’s EPS estimate is -0.75.
How many shares outstanding does Replimune Group Inc have?
Replimune Group Inc has 77,014,780 shares outstanding.
What happened to Replimune Group Inc’s price movement after its last earnings report?
Replimune Group Inc reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.706. Following the earnings report the stock price went down -1.333%.
Which hedge fund is a major shareholder of Replimune Group Inc?
Currently, no hedge funds are holding shares in REPL
---
Replimune Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.83 (59.54% Upside)
$22.83 (59.54% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $134.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.6%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.26%
12-Months-Change
Fundamentals
Return on Equity
-47.32%
Trailing 12-Months
Asset Growth
13.27%
Trailing 12-Months
Company Description
Replimune Group Inc
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
---
REPL Stock 12 Month Forecast
Average Price Target
$22.83
▲(59.54% Upside)
Technical Analysis
Best Analysts Covering REPL
1 Year
1 Year Success Rate
13/18 ratings generated profit
1 Year Average Return
+27.42%
reiterated a buy rating 9 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +27.42% per trade.
---